Conventional and prospective molecular targets in antitumour drug design. Concepts in antitumour research

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Anticancer drug development requires a deep understanding of the molecular underpinnings of pathological lesions.
• Historically, anticancer research focused on inhibiting rapidly proliferating tumor cells, leading to over 40 cytostatic agents.
• These agents target various molecular mechanisms involved in cell proliferation.

Purpose of the Study:

• To establish a rationale for drug development programs by considering the molecular basis of pathological lesions.
• To guide the selection of appropriate chemical compounds and assay systems for anticancer drug discovery.
• To shift focus towards molecular events critical for malignant disease progression, addressing limitations of current cytostatic agents.

Main Methods:

• Review of existing anticancer drug development strategies.
• Analysis of molecular mechanisms underlying tumor cell proliferation and disease progression.
• Evaluation of the efficacy of cytostatic agents in relation to therapeutic responses.

Main Results:

• The development of over 40 cytostatic agents targeting cell proliferation.
• Identification of limitations in therapeutic responses to existing cytostatic agents.
• Emerging focus on molecular events directly related to malignant disease progression.

Conclusions:

• A thorough understanding of the molecular basis of cancer is essential for rational drug development.
• Future anticancer drug discovery should prioritize targeting molecular events driving disease progression over general cell proliferation.
• This approach aims to improve therapeutic outcomes by addressing the complexities of malignant diseases.